BeOne Medicines (ONC) Total Liabilities (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Total Liabilities of $3.8 billion for Q1 2026, up 61.96% year-over-year from $2.3 billion in Q1 2025, and down 0.89% quarter-over-quarter from $3.8 billion in Q4 2025.
BeOne Medicines (ONC) Total Liabilities (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Total Liabilities for 12 consecutive years, with $3.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 61.96% year-over-year to $3.8 billion; the TTM figure through Mar 2026 stood at $3.8 billion (up 61.96% YoY), while the FY2025 annual figure was $3.8 billion, up 47.85% from the prior year.
- Total Liabilities declined to $3.8 billion in Q1 2026 per ONC's latest filing, from $3.8 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $3.8 billion in Q4 2025 and bottomed at $1.1 billion in Q4 2022.
- Historically, Total Liabilities has averaged $2.4 billion across 5 years, with a median of $2.3 billion in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities slumped 54.31% — and 2023, when it surged 106.59%.
- BeOne Medicines' Total Liabilities stood at $1.1 billion in 2022, then jumped by 106.59% to $2.3 billion in 2023, then rose by 14.14% to $2.6 billion in 2024, then soared by 47.85% to $3.8 billion in 2025, then dropped by 0.89% to $3.8 billion in 2026.
- Business Quant data shows ONC's Total Liabilities at $3.8 billion in Q1 2026, $3.8 billion in Q4 2025, and $3.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 384.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Bn |
| Mar 31, 2026 | 3.79 Bn |
| Dec 31, 2025 | 3.83 Bn |
| Sep 30, 2025 | 3.50 Bn |
| Jun 30, 2025 | 2.53 Bn |
| Mar 31, 2025 | 2.34 Bn |
| Dec 31, 2024 | 2.59 Bn |
| Sep 30, 2024 | 2.39 Bn |
| Jun 30, 2024 | 2.35 Bn |
| Mar 31, 2024 | 2.31 Bn |
| Dec 31, 2023 | 2.27 Bn |
| Sep 30, 2023 | 1.76 Bn |
| Jun 30, 2023 | 1.93 Bn |
| Mar 31, 2023 | 1.80 Bn |
| Dec 31, 2022 | 1.10 Bn |
| Sep 30, 2022 | 2.07 Bn |
| Jun 30, 2022 | 2.08 Bn |
| Mar 31, 2022 | 2.14 Bn |
| Dec 31, 2021 | 2.40 Bn |
| Sep 30, 2021 | 1.93 Bn |